Surveillance of antibiotic susceptibility pattern among shigella flexneri strain isolated in Nagpur district during three years period, January 2009-January 2012.
OBJECTIVE
In the few cases of childhood dirrhea that require the antimicrobial therapy, the correct choice of the drug depends on detailed previous knowledge of local strains and pattern of antimicrobial resistance. Shigellosis is one of the most improtant examples of this group of intestinal infections. In order to establish such parameters in Nagpur city, this study was carried out to determine the antimcrobial resistance profile of Shigella flexneri isolated from patients suffering from diahhrea admitted to Various hoapitals in Nagpur district, India.


METHODS
The study included 110 stool samples collected from patients during the 3 year period. All the isolates were characterized and confirmed by VITEK® 2 GN ID cards and antimicrobial susceptibility was tested by VITEK® 2 AST test cards.


RESULTS
We received 73 positive cultures of S. flexneri out of 110 stool samples during three year periods of January 2009 to January 2012. S. flexneri strains presented a high resistance rate to Ampicillin (100%), Chloramphenicol (76.71%), Trimethoprime-sulfamethaxazole (TMP-SMZ) (68.49%) and low resistance to third- and fourth-generation Cephalosporin. None of the isolates was found to be resistant to Ciprofloxacin (MIC ≥ 4), Norfloxacin (MIC ≥12), and Nalidixic acid (MIC ≥30).


CONCLUSIONS
Our results provide data on antimicrobial resistance to choose a proper antibiotic for the treatment of Shigellosis in our country. According to current findings, Quinolones and Cephalosporins are the drug of choice for the diarrheic patients. In conclusion, systematic monitoring is needed to identify changes in the antimicrobial resistance.
Department of Post Graduate Teaching (Microbiology), RTM Nagpur University, Nagpur, Maharashtra, India. drgomashe@rediffmail.com
Preeti G
PG
Dharmik
Ashok V
AV
Gomashe
Bharat J
BJ
Wadher
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D004403:Dysentery / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D004405:Dysentery, Bacillary / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D054539:Medication Therapy Management / Q000706:statistics & numerical data; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000706:statistics & numerical data; D008828:Microbiological Techniques / Q000295:instrumentation / Q000379:methods; D015363:Quinolones / Q000627:therapeutic use*; D012763:Shigella flexneri / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D015363:Quinolones